Our Iron Will: Who we are

Founded over 85 years ago,
Chiesi is a family-controlled,
Italian pharmaceutical company

In February 2019, Chiesi joined the Corporate Council of the National Organization for Rare Disorders (NORD) and in December 2019, Chiesi launched Chiesi Global Rare Diseases, a new business unit focused on research, development and commercialization of treatments and patient support services for rare and ultra-rare disorders.
With global headquarters in Boston, MA (USA) and European and Emerging Markets headquarters in Parma, Chiesi Global Rare Diseases works in collaboration with the Chiesi Group to harness the full resources and capabilities of our global network to bring innovative new treatment options to people living with rare diseases, many of whom have limited or no treatments available. The unit is also a dedicated partner to global leaders in patient advocacy, research, and patient care.
We work in close partnership with patients, caregivers, patients’ associations, healthcare practitioners, regulatory and pricing authorities for the benefit of patients.

To build a brighter future for the patients, we relentlessly pursue sustainable growth with passion, courage, teamwork and innovation.

VISUAL – FPO – to be recreated VISUAL – FPO – to be recreated VISUAL – FPO – to be recreated

B Corp Certified
Chiesi is the largest pharmaceutical group in the world to be awarded
B Corp Certification.

B Corp are businesses that balance purpose with profit. They are legally required to consider the impact of their decisions on their workers, customers, suppliers, community, and the environment. This is a global movement of people using business as a force for good.

VISUAL – FPO – to be recreated VISUAL – FPO – to be recreated VISUAL – FPO – to be recreated

To learn more about Chiesi Global Rare Diseases visit www.chiesiglobalrarediseases.com

Patients & Caregivers: in case of need to report an adverse drug reaction, please refer to your physician, asking him to fill in and submit the relevant case report to the concerned Health Authority, according to the Pharmacovigilance requirements in force in your Country. Nevertheless, please be kindly reminded that each patient can report any such cases directly to the national reporting system.